[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334842-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334842-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pan-cancer-interrogation-of-b7-h3-cd276-actionable-therapeutic-target-across-human-malignancies","Pan-Cancer Interrogation of B7-H3 (CD276) - Actionable Therapeutic Target Across Human Malignancies","","B7-H3 (CD276) is a B7 immune checkpoint transmembrane glycoprotein with emerging therapeutic promise. A study of 156,791 samples across 50 cancer types interrogated clinical, genomic, transcriptomic, and immunologic correlates of B7-H3 mRNA using DNA (592-gene/whole-exome) and RNA (whole-transcriptome) sequencing. B7-H3 high versus low was defined by within-cancer quartiles, with overall survival from insurance claims. Enrichment analyses and quanTIseq inferred pathway signatures and immune cell fractions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pan-cancer-interrogation-of-b7-h3-cd276-actionable-therapeutic-target-across-human-malignancies/334842/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pan-cancer-interrogation-of-b7-h3-cd276-actionable-therapeutic-target-across-human-malignancies/334842.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is B7-H3 (CD276) and why is it considered a therapeutic target?","Question",{"text":63,"@type":64},"B7-H3 (CD276) is a transmembrane glycoprotein in the B7 immune checkpoint family. It has emerged as a promising target because it is expressed across multiple cancers and is linked to immune regulation in the tumor microenvironment.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was B7-H3 expression analyzed across the 50 cancer types?",{"text":68,"@type":64},"The analysis used 156,791 samples and compared B7-H3 expression using within-cancer top versus bottom quartiles. Genomic and transcriptomic data were generated from submitted samples, and survival was assessed using insurance claims.",{"name":70,"@type":61,"acceptedAnswer":71},"What molecular and immune microenvironment patterns were associated with high B7-H3 expression?",{"text":72,"@type":64},"High B7-H3 expression aligned with enrichment of epithelial-to-mesenchymal transition, Wnt, TGFβ, and Notch signaling pathways. It was also associated with greater proportions of M1 macrophages and lower fractions of CD8+ T cells.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334842,1790179653,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","RESEARCH ARTICLE  [https://doi.org/10.1158/2767-9764.CRC-23-0546](https://doi.org/10.1158/2767-9764.CRC-23-0546)  OPEN ACCESS  \nPan-Cancer Interrogation of B7-H3 (CD276) Check for  \nupdates  \nas an Actionable Therapeutic Target Across Human Malignancies  \nCarly D. Miller1 , John R. Lozada1 , Nicholas A. Zorko1 , Andrew Elliott2 , Allison Makovec1 , Milan Radovich2 , Elisabeth I. Heath3 , Neeraj Agarwal4 , Rana R. Mckay5 , Rohan Garje6 , Bruno R. Bastos6 , Dave S. B. Hoon7 , Jacob J. Orme8 , Oliver Sartor8 , Ari VanderWalde2 , Chadi Nabhan2 , George Sledge2 , Eugene Shenderov9 , Scott M. Dehm1 , 10 , Emil Lou1 , Jeffrey S. Miller1 , Justin H. Hwang1 , and Emmanuel S. Antonarakis1  \nABSTRACT  \nB7-H3 (CD􀀂􀀃􀀄) is a transmembrane glycoprotein of the B7 immune checkpoint superfamily that has emerged as a promising therapeutic target. To better understand the applicability of B7-H3–directed therapies, we analyzed 156,791 samples comprising 50 cancer types to interrogate the clinical, genomic, transcriptomic, and immunologic correlates ofB7-H3 mRNA expression. DNA (592-gene/whole-exome) and RNA (whole-transcriptome) sequencing was performed from samples submitted to Caris Life Sciences. B7-H3 high versus low expression was based on top and bottom quartiles for each cancer type. Patients’ overall survival was determined from insurance claims data. Pathway analysis was performed using gene set enrichment analyses. Immune cell fractions were inferred using quanTIseq. B7-H3 is expressed across several human malignancies including prostate, pancreatic, ovarian, and lung cancers. High B7-H3 expression is associated with differences in overall survival, possibly indicating a prognostic role of B7-H3 for some cancers. When examining molecular features across all cancer types, we did not identify recurrent associations between B7-H3  \nexpression and genetic alterations in TP􀀅􀀆 , RB􀀇, and KRAS. However, we find consistent enrichment of epithelial-to-mesenchymal transition, Wnt, TGFβ, and Notch signaling pathways. In addition, tumors with high B7-H3 expression are associated with greater proportions of M1 macrophages, but lower fractions of CD8+ T cells. We have begun to define the genomic, transcriptomic, clinical, and immunologic features associated with B7-H3 expression in 50 cancer types. We report novel clinical and molecular features of B7-H3–high tumors which may inform how current B7-H3 therapeutics should be deployed and prioritized.  \nSignificance: B7-H3–targeting therapeutics have shown promising results in initial clinical trials. In this pan-cancer analysis of B7-H3 mRNA expression, we found that B7-H3 exhibits robust expression in many common cancer types. These results may inform further development of B7-H3– targeting therapeutics and may guide clinical decisions for patients with limited treatment options.  \nIntroduction  \nIn recent years, targeted cancer therapies have gained popularity due to their ability to target both solid tumors and hematologic malignancies refractory to traditional therapies (1) . Immune checkpoint inhibitors (ICI) targeting PD-1, PD-L1, and CTLA-4 have become widely utilized because of their efficacy in various clinical contexts where traditional treatments have failed (2) . ICIs have  \n1 Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. 2 Caris Life Sciences, Phoenix, Arizona. 3 Karmanos Cancer Institute, Detroit, Michigan.  \n4 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. 5 University of California San Diego, La Jolla, California. 6 Miami Cancer Institute, Baptist Health South Florida, Miami, Florida. 7 Saint John’s Cancer Institute PHS, Santa Monica, California. 8 Mayo Clinic Comprehensive Cancer Center, Rochester, Minnesota. 9 The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland. 10 Departments of Laboratory Medicine and Pathology and Urology, University of Minnesota, Minneapolis, Minnesota.  \nshown success i","cbCaipVSlnmqWdKu","https://ap.wps.com/l/cbCaipVSlnmqWdKu","pdf",7176080,11,"English","# Abstract and significance\n# Introduction\n# Methods and analysis overview\n## Expression stratification and survival assessment\n## Genomic, transcriptomic, and pathway analyses\n## Immune microenvironment inference\n# Findings across cancer types\n## Expression patterns and prognostic associations\n## Lack of recurrent genetic associations\n## Enriched signaling pathways\n# Interpretation and therapeutic implications","[{\"question\":\"What is B7-H3 (CD276) and why is it considered a therapeutic target?\",\"answer\":\"B7-H3 (CD276) is a transmembrane glycoprotein in the B7 immune checkpoint family. It has emerged as a promising target because it is expressed across multiple cancers and is linked to immune regulation in the tumor microenvironment.\"},{\"question\":\"How was B7-H3 expression analyzed across the 50 cancer types?\",\"answer\":\"The analysis used 156,791 samples and compared B7-H3 expression using within-cancer top versus bottom quartiles. Genomic and transcriptomic data were generated from submitted samples, and survival was assessed using insurance claims.\"},{\"question\":\"What molecular and immune microenvironment patterns were associated with high B7-H3 expression?\",\"answer\":\"High B7-H3 expression aligned with enrichment of epithelial-to-mesenchymal transition, Wnt, TGFβ, and Notch signaling pathways. It was also associated with greater proportions of M1 macrophages and lower fractions of CD8+ T cells.\"}]","Pan-Cancer Interrogation of B7-H3 (CD276) - Actionable Therapeutic Target Across Human Malignancies | PDF",1790008530,28]